Pre-emptive, early, and delayed alendronate treatment in a rat model of knee osteoarthritis: effect on subchondral trabecular bone microarchitecture and cartilage degradation of the tibia, bone/cartilage turnover, and joint discomfort

OBJECTIVE

Bisphosphonates are considered potential disease modifying osteoarthritis (OA) agents. The present study investigated the efficacy of pre-emptive, early, and delayed alendronate (ALN) treatment initiation on subchondral trabecular bone and cartilage in low-dose monosodium iodoacetate (MIA)-induced knee OA in rats.

METHODS

Male rats received pre-emptive (n = 12, day 0-end of week 2), early (n = 12, end of week 2-end of week 6), or delayed (n = 12, end of week 6-end of week 10) ALN treatment (30 μg/kg/week). Pre-emptive ALN-treated rats were scanned using in vivo micro-computed tomography (micro-CT) after 2 weeks and then sacrificed, early ALN-treated rats were scanned after 2 and 6 weeks and sacrificed, and the delayed ALN-treated rats were scanned after 2, 6, and 10 weeks of OA induction and sacrificed. After sacrifice, bone histomorphometry and histology of the tibia and biomarker analyses were undertaken. Changes in hind limb weight-bearing were assessed from day -1 until day 14.

RESULTS

MIA-induced pathological features similar to progressive human OA in the cartilage and subchondral bone. Pre-emptive ALN treatment preserved subchondral trabecular bone microarchitecture, prevented bone loss, decreased bone turnover and joint discomfort. Pre-emptive ALN treatment had moderate effects on cartilage degradation. Early and delayed ALN treatments prevented loss of trabeculae and decreased bone turnover, but had no significant effect on cartilage degradation.

CONCLUSION

ALN prevented increased bone turnover and preserved the structural integrity of subchondral bone in experimental OA. The time point of treatment initiation is crucial for treating OA. Treating both the subchondral bone and cartilage in OA would be clinically more beneficial.

A comparative analysis of water-soluble and blood-pool contrast agents for in vivo vascular imaging with micro-CT

RATIONALE AND OBJECTIVES

In recent years, micro-computed tomography (micro-CT) has emerged as a high-resolution modality for vascular exploration in vivo. Several x-ray contrast agents for in vivo imaging are on the market and are based on different formulations. The objective of this study was to compare contrast-related and pharmacokinetic properties of a water-soluble compound containing iomeprol (Iomeron 400) and blood-pool agents (eXIA160XL, AuroVist 15 nm, and ExiTron nano 12000) for the identification of suitable in vivo vascular imaging applications.

MATERIALS AND METHODS

Forty-four healthy C57BL/6J mice were used in this study. Iomeprol was administered with a continuous infusion protocol; the other agents as a bolus. Anatomical micro-CT was applied at the head, neck, and lower hind limb before (baseline) and immediately after contrast injection, and used to quantify contrast-related properties of the agents. Dynamic micro-CT was applied at the same regions to characterize the agents pharmacokinetics.

RESULTS

All contrast media revealed safe, except for eXIA160XL, which caused death in four of eight tested animals and was therefore excluded early from the study. AuroVist 15 nm provided the highest attenuation (2.33/mm) as compared to iomeprol (1.97/mm) and ExiTron nano 12000 (1.58/mm) and a maximum temporal variation of contrast of 20% after 30 minutes, but the appearance of a dark skin staining did not allow multiple injections of the agent. Iomeprol passively diffused across capillary membranes, and after 30 minutes doubled the tissue contrast with respect to its initial levels. ExiTron nano 12000 revealed temporal variations of contrast below 10% and significantly reduced clearance rates after the third consecutive injection.

CONCLUSION

AuroVist 15 nm is best suited for anatomical investigation of the vascular network, while the high extravasation levels of iomeprol can be exploited for perfusion analysis. ExiTron nano 12000 is indicated for use in longitudinal monitoring with repeated injections.